DDInter636 DDInter1752
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Empagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Empagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Timolol
Empagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Empagliflozin {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Empagliflozin may cause a minor interaction that can limit clinical effects when taken with Amcinonide
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Empagliflozin may lead to a major life threatening interaction when taken with Gatifloxacin